Solomon Husain1,2, Shivangi Lohia1,3, Valentina Petkov4, Timothy Blackwell1, Samuel Swisher-McClure2, Aviram Mizrachi5, Luc G Morris1, Marc A Cohen1, Richard J Wong1, Benjamin R Roman1. 1. Department of Head and Neck Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA. 2. Penn Medicine Abramson Cancer Center, Philadelphia, Pennsylvania, USA. 3. Department of Otolaryngology, Henry Ford Health Systems, Detroit, Michigan, USA. 4. Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, Maryland, USA. 5. Otorhinolaryngology Head and Neck Surgery, Rabin Medical Center, Petah Tikva and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Abstract
BACKGROUND: Human papilloma virus testing for oropharyngeal squamous-cell carcinoma has been recommended by the National Comprehensive Cancer Network since 2012. We examine disparities, reported rates of human papillomavirus (HPV) testing, and the impact on these findings of limitations with the variable in database registries. METHODS: The HPV variable was queried for patients with oropharyngeal squamous carcinoma (OPSCC) from 2013 to 2016 in National Cancer Data Base (NCDB) and Surveillance, Epidemiology, and End Results (SEER). Multivariable regression was used to identify disparities based on sociodemographic variables. Sensitivity analyses were used to investigate limitations of the variable. RESULTS: Despite limitations in the HPV variable in the databases, there was less than 100% adherence to recommended testing, and there were significant disparities in multiple sociodemographic variables. For example, in NCDB 70% of white versus 60.4% of black patients were tested (odds ratio [OR] 0.75, confidence interval [CI] 0.66-0.85, p ≤ 0.0001); in SEER 59.8% of white and 47.6% of black patients were tested (OR 0.73, CI 0.67-0.81; p ≤ 0.0001). CONCLUSIONS: Disparities exist among patients undergoing testing for HPV-associated OPSCC and adherence to guideline recommended HPV testing has been suboptimal. In addition, the HPV variable definition, especially as it relates to p16 positivity, and use in these two registries should be improved.
BACKGROUND: Human papilloma virus testing for oropharyngeal squamous-cell carcinoma has been recommended by the National Comprehensive Cancer Network since 2012. We examine disparities, reported rates of human papillomavirus (HPV) testing, and the impact on these findings of limitations with the variable in database registries. METHODS: The HPV variable was queried for patients with oropharyngeal squamous carcinoma (OPSCC) from 2013 to 2016 in National Cancer Data Base (NCDB) and Surveillance, Epidemiology, and End Results (SEER). Multivariable regression was used to identify disparities based on sociodemographic variables. Sensitivity analyses were used to investigate limitations of the variable. RESULTS: Despite limitations in the HPV variable in the databases, there was less than 100% adherence to recommended testing, and there were significant disparities in multiple sociodemographic variables. For example, in NCDB 70% of white versus 60.4% of black patients were tested (odds ratio [OR] 0.75, confidence interval [CI] 0.66-0.85, p ≤ 0.0001); in SEER 59.8% of white and 47.6% of black patients were tested (OR 0.73, CI 0.67-0.81; p ≤ 0.0001). CONCLUSIONS: Disparities exist among patients undergoing testing for HPV-associated OPSCC and adherence to guideline recommended HPV testing has been suboptimal. In addition, the HPV variable definition, especially as it relates to p16 positivity, and use in these two registries should be improved.
Authors: Florence K Keane; Yui-Hui Chen; Bridget A Neville; Roy B Tishler; Jonathan D Schoenfeld; Paul J Catalano; Danielle N Margalit Journal: Cancer Date: 2015-04-14 Impact factor: 6.860
Authors: Janine M Rotsides; Jamie R Oliver; Lindsey E Moses; Moses Tam; Zujun Li; David Schreiber; Adam S Jacobson; Kenneth S Hu; Babak Givi Journal: Otolaryngol Head Neck Surg Date: 2020-07-14 Impact factor: 3.497
Authors: Kevin Y Zhan; Antoine Eskander; Stephen Y Kang; Matthew O Old; Enver Ozer; Amit A Agrawal; Ricardo L Carrau; James W Rocco; Theodoros N Teknos Journal: Oral Oncol Date: 2017-09-07 Impact factor: 5.337
Authors: Caryn E Peterson; Shaveta Khosla; Lucy F Chen; Charlotte E Joslin; Faith G Davis; Marian L Fitzgibbon; Sally Freels; Kent Hoskins Journal: J Cancer Res Clin Oncol Date: 2016-06-01 Impact factor: 4.553
Authors: Derek D Kao; Rocco M Ferrandino; Deborah C Marshall; Tinaye Mutetwa; Brett Miles; Joshua M Bauml; Keith M Sigel Journal: Int J Otolaryngol Date: 2022-05-02